Drugs / ChAd-triCoV/Mac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06381739 | Mar 2025 → Dec 2026 expected | COVID-19 | McMaster University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAd-triCoV/Mac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06381739 ↗ |
| Modality | Vaccine | “this new COVID-19 vaccine” NCT06381739 ↗ |
| Route | Inhaled | “aerosolized and inhaled via a mouthpiece” NCT06381739 ↗ |